New Diet Pill to Be Sold at Drug Stores

Wednesday, 17 Apr 2013 03:53 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
Vivus Inc. President Peter Tam said U.S. health regulators' approval to sell its diet pill Qsymia through retail pharmacies removed "a major barrier" to the drug's adoption and paved the way for a direct-to-consumer campaign to be launched later this year.
 
"We are keeping all options open in terms of increasing the commercialization support for Qsymia," Tam told Reuters in a phone conversation from his Mountain View, California office.
 
Since Qsymia's launch in September, Vivus has been struggling to improve sales of the drug.

The company has earlier blamed weak adoption of the pill on limited reimbursement and a restricted Risk Evaluation and Mitigation Strategy (REMS), or a risk managing plan, that allows the drug to be sold only through mail-order pharmacies.
 
The U.S. Food and Drug Administration accepted Vivus's proposal to modify the REMS and allow Qsymia's sale through certified retail pharmacies, where the drug is expected to be available within 90 days, the company said.
 
Vivus's largest shareholder, First Manhattan Co (FMC), which has been critical of the company's marketing plan and pushed for a partnership on the drug, stepped up its attack last week when it said it anticipated the company to get an REMS modification, but that would not guarantee Qsymia's success.
 
President Tam refused to comment on FMC's statement, but said "the REMS modification was a monumental task. It's not something about which anyone can say — oh, it was expected."
 
"We have previously guided to the Street that typically the FDA would take six months to review and render a decision [on an REMS modification]. Today, is exactly six months from the time we submitted."
 
Tam added that the company was in discussions with insurers and pharmacy benefit managers to improve Qsymia's reimbursement, but it was still scouting for a buyer for its yet-to-be-launched erectile dysfunction drug Stendra that won U.S. regulators' approval in April 2012.

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Lazy Lifestyle Dangerous as Smoking: Study

Friday, 24 Oct 2014 16:09 PM

Leading a lazy lifestyle can put you at risk as much as smoking. That's the upshot of a landmark report by Public Health . . .

Weight Loss Surgery Brings Risk of Severe Headaches: Study

Wednesday, 22 Oct 2014 17:21 PM

After weight-loss surgery, some patients may be at risk for developing severe headaches, a new study suggests.
In  . . .

Music Makes Exercise Feel Easier: Study

Wednesday, 22 Oct 2014 16:21 PM

Listening to your favorite songs while exercising makes the workout feel less strenuous, a new study finds.
 . . .

Most Commented

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved